Effect of Flavored on!® Nicotine Pouch Products on Smoking Behaviors: a SMART Study
NCT ID: NCT06072547
Last Updated: 2024-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2023-09-11
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be provided with research products to use for 6 weeks. Researchers will compare the reduction in cigarette smoking between participants with access to a complete flavor profile of research products and participants with access to only the Original (non-flavored) variety of research product to see if reduction in cigarette smoking is greater among those with access to flavored research products.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Controlled Trial to Evaluate the Impact of ZYN Nicotine Pouch Products on Cigarette Usage and BoExp in Adult Smokers Over a 12-week Period
NCT06568900
Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches
NCT05664672
Effects of an Oral Nicotine Product in Smokeless Tobacco Users
NCT05280769
Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
NCT00710034
Use of Nicotine Pouches Among Daily Smokers
NCT06043362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this design, there are three configurations:
1. Access to complete flavor profile (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) for the entire six-week trial period (Group I);
2. Access to Original only for the entire six-week trial period (Group IIa); and
3. Access to Original only for the first three-week period and then access to complete flavor profile for the second three-week period (Group IIb).
This study will involve approximately 7 weeks (including the baseline period) of study participation in a home use test with daily surveys, weekly surveys, and a 6-month follow-up survey after the trial period. Approximately 400 participants will be recruited. A total of 150 participants will be randomized to Group I, 125 to Group IIa, and 125 to Group IIb.
After consenting and screening procedures, participants will be followed for 3-7 days to establish baseline measures of cigarettes smoked per day. During this baseline period at least two CO readings will be collected. Participants randomized into Group I will enter a seven-day trial period to try all flavors of research products. This trial period is intended to allow participants to identify their preferred flavor(s). After the trial period, they will then complete five additional weeks of home use testing with ad libitum product trial of research products with free choice of the flavors available in this study.
Likewise, following the baseline period, participants randomized into Group II will be provided with the Original variety of research products to use for the next three weeks. At the three-week point, participants in Group IIa will continue with the Original variety of research product for the remaining three weeks and Group IIb will switch to having access to all flavors of research products for the remaining three weeks. Group IIb will enter a seven-day trial period to try all flavors of research products (a total of seven packs - one of each flavor will be provided). This trial period is intended to allow participants to identify their preferred flavor(s). After the trial period, they will then complete two additional weeks of home use testing with ad libitum product trial of research products with free choice of the flavors available in this study.
Participants will be invited to complete a six-month follow-up survey to gain insights about their tobacco use and related factors after the end of the product trial.
Analysis will be conducted to compare outcomes between:
1. Group I vs. Group II at week 3
2. Group I vs. Group IIa at week 6
3. Group IIa vs. Group IIb at week 6 among non-responders at week3
4. Group IIa and Group IIb at week 6 among responders at week 3
5. Group I and Groups IIb at week 6
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Complete flavor profile of on! nicotine pouches
This study arm will provided with access to all varieties of 4mg on! nicotine pouch products throughout the trial.
Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)
Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
Non-Flavored on! nicotine pouches only
This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
Access to Original on! 4mg nicotine pouches
Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
Non-Flavored then complete flavor on! nicotine pouches
This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products during the first 3 weeks of the trial and then access to all varieties of 4mg on! nicotine pouch products during the last 3 weeks of the trial.
Non-Flavored then complete flavor on! nicotine pouches
Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)
Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
Access to Original on! 4mg nicotine pouches
Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
Non-Flavored then complete flavor on! nicotine pouches
Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy adults who smoke cigarettes and are 22 to 65 years of age (inclusive) at screening.
3. Smokes an average of at least 5 cigarettes per day for the last 12 months.
4. Does not intend to use an FDA-approved treatment for nicotine dependence within the next 60 days (as assessed at screening).
5. Interested in replacing combustible cigarettes with a smoke-free tobacco product.
6. Willing and able to comply with the requirements of the study.
7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.
Exclusion Criteria
2. Participant, or their first-degree relative (e.g., parent, sibling, child, spouse) or household member, is a current or former employee of the tobacco or e-vapor industry.
3. Participant, or their first-degree relative (e.g., parent, sibling, child, spouse) or household member is a named party or class representative in litigation involving a tobacco or e-vapor company.
4. Participant, or their first-degree relative (e.g., parent, sibling, child, spouse), or household member, is a current or former employee of a marketing consultant, market research firm, advertising or promotions agency, television or radio station, magazine or newspaper, government regulatory agency or public policy advocacy group, or law firm or legal department of a company.
5. Participant self-reports being "in poor health."
6. Participants of childbearing potential (CBP) who have a positive pregnancy test (as assessed at screening) or are nursing or planning to become pregnant during their participation.
7. Participant has an allergy/sensitivity to menthol or menthol-containing products or phenylalanine.
8. Participant has any other self-reported health restrictions.
9. Participant self-reports cardiovascular disease, cancer, diabetes, or is being treated for high blood pressure.
10. Participant self-reports periodontal disease, gum disease or bleeding, open mouth sores or ulcers.
11. Participant self-reports as wanting to stop using tobacco products in the next 60 days.
12. Participant has participated in one tobacco research study in the past 30 days OR a tobacco research study lasting two weeks or longer in the past 90 days.
13. Participant is unable to read, speak or understand English.
14. Participants who ever used at least a pack of nicotine pouch products or currently uses nicotine pouch products.
15. Participant who smokes marijuana more than once a week.
16. Heterosexually active participants of CBP (not sterilized by tubal ligation, oophorectomy, hysterectomy, or other surgical methods, or post-menopausal) that do not agree to practice medically appropriate methods of birth control (or remain abstinent) during the course of the trial and for 30 days after the last use of the research product. Medically acceptable methods of birth control include: vasectomy, vaginal diaphragm with spermicide, intrauterine device, hormonal birth control (oral, injected, patch, or implanted), condom with spermicide, or sponge with spermicide.
17. Taking psychoactive medications (e.g., antipsychotics or mood stabilizers).
18. Cannot participate in the study for any reason (e.g., medical, psychiatric, and or social reason) as judged by the Investigator or designated medical staff based on all available information from the screening period.
22 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rose Research Center, LLC
INDUSTRY
Altria Client Services LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hui Cheng, PhD
Role: PRINCIPAL_INVESTIGATOR
ALCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rose Research Center
Raleigh, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cheng HG, Rose JE, Karelitz JL, Botts DR, Botts TL, Willette PN, Cohen G. Effect of Flavored on! Nicotine Pouch Products on Smoking Behaviors: Protocol for a Sequential, Multiple Assignment, Randomized Controlled Trial. JMIR Res Protoc. 2024 Jun 21;13:e56565. doi: 10.2196/56565.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALCS-REG-23-04-OTDN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.